Microfluidic nanoparticle synthesis for oral solid dosage forms: A step toward clinical transition processes
Articolo
Data di Pubblicazione:
2024
Citazione:
Microfluidic nanoparticle synthesis for oral solid dosage forms: A step toward clinical transition processes / L. Morelli, E. Ochoa, L. Salvioni, M. Davide Giustra, B. De Santes, F. Spena, L. Barbieri, S. Garbujo, G. Tomaino, B. Novati, L. Bolis, S. Moutaharrik, D. Prosperi, L. Palugan, M. Colombo. - In: INTERNATIONAL JOURNAL OF PHARMACEUTICS. - ISSN 0378-5173. - 652:(2024 Mar 05), pp. 123850.1-123850.8. [10.1016/j.ijpharm.2024.123850]
Abstract:
Nanomedicine provides various opportunities for addressing medical challenges associated with drug bioavailability, stability, and efficacy. In particular, oral nanoparticles (NPs) represent an alternative strategy to enhance the solubility and stability of active ingredients through the gastrointestinal tract. The nanocarriers could be used for both local and systemic targeting, enabling controlled release of encapsulated drugs. This approach allows more efficient therapies. In this work, we aim to develop reliable oral solid dosage forms incorporating NPs produced by either one pot synthesis or continuous production, following protocols that yield highly consistent outcomes, promoting their technology transfer and clinical use. Microfluidics technology was selected to allow an automated and highly productive synthetic approach suitable for the highly throughput production. In particular, innovative systems, which combine advantage of NPs and solid dosage formulation, were designed, developed, and characterized demonstrating the possibility to obtaining oral administration. The resulting NPs were thus carried on oral dosage forms, i.e., pellets and minitablets. NPs resulted stable after dosage forms manufacturing, leading to confidence also on protection of encapsulated drugs. Indomethacin was used as a tracer to test biopharmaceutical behaviour. Anti-inflammatories or cytotoxic chemotherapeutics could be vehiculated leading to a breakthrough in the treatment of severe diseases allowing the oral administration of these drugs. We believe that the advancement achieved with the results of our work paves the way for the progression of nanoproducts into clinical transition processes.
Tipologia IRIS:
01 - Articolo su periodico
Keywords:
Applications; Clinical transitions; Microfluidics; Multi-units dosage forms; Oral delivery; Polymeric nanoparticles;
Elenco autori:
L. Morelli, E. Ochoa, L. Salvioni, M. Davide Giustra, B. De Santes, F. Spena, L. Barbieri, S. Garbujo, G. Tomaino, B. Novati, L. Bolis, S. Moutaharrik, D. Prosperi, L. Palugan, M. Colombo
Link alla scheda completa:
Link al Full Text: